BeyondSpring aiming for $100M IPO

BeyondSpring Pharmaceuticals Inc. (New York, N.Y.) proposed to raise up to $100 million in an IPO on NASDAQ underwritten by Citigroup, Guggenheim Securities, FBR, China Renaissance and Trout Capital.

The company plans to advance plinabulin (BPI-2358) into two global Phase II/III trials, beginning this quarter and in 1H17, to treat neutropenia. The first study will test the halimide-derived tumor vascular disrupting agent (VDA) in combination with docetaxel in solid tumors, including advanced breast cancer, hormone-refractory prostate cancer and advanced non-small cell lung cancer. The second trial will evaluate plinabulin plus myelosuppressive agents other than docetaxel in patients with solid tumors and lymphomas. The company expects first data in 2H17 and 1H19, respectively...